IBM Micromedex: Integration with the Philips Tasy EHR
5
DATA SHEET IBM Micromedex: Integration with the Philips Tasy EHR Automated drug interaction screening IBM® Micromedex® is a clinical decision support (CDS) system that provides evidence-based drug, disease and patient education information at the point of care. The integration of IBM Micromedex into the Philips Tasy electronic health record (EHR) helps make drug interactions information accessible directly within the workflow of physicians, pharmacists and nurses, helping them improve both clinical and operational efficiency. IBM Micromedex is supported by an editorial board comprised of specialized healthcare professionals who evaluate medical literature with high-level reviews, using a robust editorial process, which is accredited by the National Institute for Health and Care Excellence (NICE) 1 . Solutions that integrate with the Philips Tasy EHR: – IBM® Micromedex® Medication Advisory Screening (MAS) – Integrated clinical knowledge from IBM Micromedex via InfoButton Access “With the integration of IBM Micromedex, you can see a patient’s drug interaction profile in a matter of seconds—you can do it for all of the hospital’s patients—and the information is automatically updated. This saves the healthcare professionals time, which they can dedicate to the patient.” – Andre Mallman, IT and Telecom Manager at Hospital São Vicente de Paulo Includes selected medications approved by the National Health Surveillance Agency (ANVISA) in Brazil 3
Transcript of IBM Micromedex: Integration with the Philips Tasy EHR
DATA SHEET
IBM Micromedex: Integration with thePhilips Tasy EHR Automated drug interaction screening
IBM® Micromedex® is a clinical decision support (CDS) system that provides evidence-based drug, disease and patient education information at the point of care.
The integration of IBM Micromedex into the Philips Tasy electronic health record (EHR) helps make drug interactions information accessible directly within the workflow of physicians, pharmacists and nurses, helping them improve both clinical and operational efficiency.
IBM Micromedex is supported by an editorial board comprised of specialized healthcare professionals who evaluate medical literature with high-level reviews, using a robust editorial process, which is accredited by the National Institute for Health and Care Excellence (NICE)1.
Solutions that integrate with the Philips Tasy EHR:
– IBM® Micromedex® Medication Advisory Screening (MAS)
– Integrated clinical knowledge from IBM Micromedex via InfoButton Access
“With the integration of IBM Micromedex, you can see a patient’s drug interaction profile in a matter of seconds—you can do it for all of the hospital’s patients—and the information is automatically updated. This saves the healthcare professionals time, which they can dedicate to the patient.”
– Andre Mallman, IT and Telecom Manager at Hospital São Vicente de Paulo
Includes selected medications approved by the National Health Surveillance Agency (ANVISA) in Brazil
3
Drug interactions types: – drug-drug– drug-food– drug ethanol– drug-laboratory– drug-tobacco– drug-disease
Integration of IBM Micromedex in the Philips Tasy EHR – How does it work?When the clinician enters the medication order in the EHR, a pop-up displays the drug interactions found for that order. The interactions can also be checked before finishing the medication order, by right-clicking on Check Drug Interactions
Watson Health © IBM Corporation 2018 2
– drug-drug– drug-food– drug ethanol– drug-laboratory– drug-tobacco– drug-disease
Strength of documentation ratings ExcellentGoodFairUnknown
Request for drug interactions
screening sent
Results of the drug interacations screening returned
Severity ratings Contraindicated Major Moderate Minor Unknown
IBM Micromedex Philips Tasy EMR
DRUG Number of Interactions: 11 Maximum Severity: ContraindicatedDrug Interaction
Interacting drug CLARITROMICINA 500MG COMPRIMIDO GFC 100854 CLARITHROMYCIN
Secondary Item SINVASTATINA 20 MG COMPRIMIDO GFC 103470 SIMVASTATINAlert Concurrent use of CLARITHROMYCIN and SIMVASTATIN may result in an increased risk of myopathy or rhabdomyolysis
Severity: ContraindicatedDocumentation: GOOD
Details
Interacting drug AAS 100MG COMPRIMIDO GFC 108555 ASPIRIN
Secondary Item VARFARINA 2,5 MG COMPRIMIDO GFC 104048 WARFARIN SODIUMAlert Concurrent use of WARFARN and ANTIPLATELET AGENTS may result in an increased risk of bleeding
Severity: MajorDocumentation: FAIR Details
S
Interacting drug BUSCOPAN SIMPLES 20MG AMPOLA 1ML GFC 110292 BUTYLSCOPOLAMINE BROMIDE
Secondary Item DONEPEZILA 5MG COMPRIMIDO GFC 111334 DONEPEZIL HYDROCHLORIDEAlert Concurrent use of DONEPEZIL and SEIZURE LOWERING AGENTS may result in reduced seizure threshold
Severity: MajorDocumentation: FAIR
Details
S
Interacting drug CLARITROMICINIA 500MG COMPRIMIDO GFC 100854 CLARITHROMYCIN
Secondary Item DONEPEZILA 5MG COMPRIMIDO GFC 111334 DONEPEZIL HYDROCHLORIDEAlert Concurrent use of DONEPEZIL and QT INTERVAL PROLONGING AGENTS may result in increased risk of QT-interval prolongation and torsade de point
Severity: MajorDocumentation: GOOD Details
S
O filtro escolhido trará as interações com a severidade ou documentação iguais á escholhida e/ou maiores. Ex: Filtro MODERATE trará interações Moderate, Major e Contraindicated.
Severity from Contraindicated
Major Moderate Minor Unknown
Documentation rating from Excellent
Good Fair Unknown
Drug Lab Allergy Precautions Indredient duplication
Food Tobacco Pregnancy TC Duplication Proxy disease
Ethanol Disease Lactation Antagonism Patient disease
ü ü ü ü ü
ü ü ü ü ü
ü ü ü ü ü
1
2
3
Features of the automated drug interaction screening in Philips Tasy
FiltersThe clinician can filter by severity, strength of documentation or interaction type, to limit the information displayed.
Summary for interaction typeThe clinician can view a summary of the number of interactions of that type (drug, disease, food, allergy, etc.) that were identified, and the maximum interaction severity found for that type.
The interaction itself– Displays the prescribed item (for example: Claritromicina 500mg
COMPRIMIDO), the drug code (GFC) and the active ingredient involved in the interaction (for example: Clarithromycin).
– The alert displays a summary of the outcome that the interaction may cause.
– Details will give additional information on the interaction, such as Clinical Management and Literature.
1
2
3
Watson Health © IBM Corporation 2018 3
4Watson Health © IBM Corporation 2018
Integrated clinical knowledge from IBM Micromedex via InfoButton AccessIntegration provides direct links from within the Philips Tasy EHR to clinically relevant information on drugs for healthcare professionals:
– Adult and pediatric dosing, dosing adjustments, off-label uses, adverse effects, monitoring, toxicology and more
Get connectedRepresentatives of Dot.Lib, authorized distributor of Truven Health Analytics, part of the IBM Watson Health business.
BrazilHenrique PereiraAccount [email protected]+55 11 98558-8025+55 (11) 3253-7553
Jorge SiqueiraClinical Solutions [email protected]+55 11 94219-6209+55 11 3253-7553
Argentina, Chile, Colombia, Ecuador, Peru, Uruguay and Venezuela:Miguel [email protected]+57-1-704-5756
Mexico:Napoleón [email protected]+52 1 55 2190 8657María del Carmen Ló[email protected]+52-1-55-3248-7467
Representatives of Rubali Professionals, authorized distributor of of Truven Health Analytics, part of the IBM Watson Health business
Caribbean and Central America:Ruben [email protected]+787-791-3909
HPD
1240
4-US
EN-0
1
© Copyright IBM Corporation 2018
IBM Corporation Route 100 Somers, NY 10589
Produced in the United States of America May 2018
IBM, the IBM logo and ibm.com and IBM Watson Health are trademarks of IBM Corporation in the United States, other countries or both. Truven Health Analytics and its respective logo are trademarks of Truven Health Analytics in the United States, other countries or both. All other company or product names are registered trademarks or trademarks of their respective companies. A current list of IBM trademarks is available on the Web at
“Copyright and trademark information” at www.ibm.com/legal/copytrade.shtml.
This document is current as of the initial date of publication and may be changed by IBM at any time. Not all offerings are available in every country in which IBM operates.
The information in this document is provided “as is” without any warranty, express or implied, including without any warranties of merchantability, fitness for a particular purpose and any warranty or condition of non-infringement. IBM products are warranted according to the terms and conditions of the agreements under which they are provided.
The client is responsible for ensuring compliance with all applicable laws and regulations applicable to it.
IBM does not provide legal advice or represent or warrant that its services or products will ensure that the client is in compliance with any law or regulation.
The performance data and client examples cited are presented for illustrative purposes only. Actual performance results may vary depending on the specific configurations and operating conditions. It is the user’s responsibility to evaluate and verify the operation of any other products or programs with IBM product and programs.
Statement of Good Security Practices: IT system security involves protecting systems and information through prevention, detection and response to improper access from within and outside your enterprise. Improper access can result in information being altered, destroyed, misappropriated or misused or can result in damage to or misuse of your systems, including for use in attacks on others. No IT system or product should be considered completely secure and no single product, service or security measure can be completely effective in preventing improper use or access. IBM systems, products and services are designed to be part of a lawful, comprehensive security approach, which will necessarily involve additional operational procedures, and may require other systems, products or services to be most effective. IBM does not warrant that any systems, product or services are immune from, or will make your enterprise immune from, the malicious or illegal conduct of any party.
Get connectedemail: [email protected]
About IBM Watson HealthEach day, professionals throughout the health ecosystem make powerful progress toward a healthier future. At IBM Watson Health, we help them remove obstacles, optimize efforts and reveal new insights to support the people they serve. Working across the landscape, from payers and providers to governments and life sciences, we bring together deep health expertise; proven innovation; and the power of artificial intelligence to enable our customers to uncover, connect and act — as they work to solve health challenges for people everywhere.
For more information on IBM Watson Health, visit:ibm.com/watsonhealth
